

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT

REMARKS

Any fees that may be due in connection with filing this paper, or with this application during its entire pendency, may be charged to Deposit Account No. 50-1213.

The specification and the claims are amended to correct obvious typographical, spelling, and formatting errors. The first authorship of several references cited in the specification is also corrected.

No new matter has been added.


Entry of this amendment is respectfully requested.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By: _____

Stephanie Seidman
Registration No. 33, 779

Attorney Docket No. 24745-1607
Address all correspondence to:
Stephanie Seidman
HELLER EHRMAN WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, Suite 600
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/990

AUG 09 2001

RECEIVED

Applicant: **Madison et al.**

Serial No.: 09/776,191

Filed: February 2, 2001

For: **NUCLEIC ACID MOLECULES
ENCODING TRANSMEMBRANE
SERINE PROTEASES, THE
ENCODED PROTEINS AND
METHODS BASED THEREON**

Art Unit: 1614

Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, D.C. 20231, on this date.

08/03/01

Date

Kelly M. Fischer
Kelly M. Fischer

**ATTACHMENT TO THE PRELIMINARY AMENDMENT
MARKED UP PARAGRAPHS AND CLAIMS (37 CFR §1.121)**

IN THE SPECIFICATION:

Please amend the specification as follows:

Please amend the paragraph on page 1, lines 1-31, as follows:

For U.S. purposes, benefit of priority under 35 U.S.C. §119(e) to U.S. provisional application Serial No. 60/179,982, to Edwin L. Madison and Edgar O. Ong, filed February 3, 2000, entitled "NUCLEOTIDE AND PROTEIN SEQUENCES OF A TRANSMEMBRANE SERINE PROTEASE AND METHODS BASED THEREOF"; to U.S. provisional application Serial No. 60/183,542, to Edwin L. Madison and Edgar O. Ong, filed February 18, 2000, entitled "NUCLEOTIDE AND PROTEIN SEQUENCES OF A TRANSMEMBRANE SERINE PROTEASE AND METHODS BASED THEREOF"; to U.S. provisional application Serial No. 60/213,124, to Edwin L. Madison and Edgar O. Ong, filed June 22, 2000, entitled "NUCLEOTIDE AND PROTEIN SEQUENCES OF A TRANSMEMBRANE SERINE PROTEASE AND METHODS BASED THEREOF"; to U.S. provisional application Serial No. 60/220,970, to Edwin L. Madison and Edgar O. Ong, filed July 26, 2000, entitled "NUCLEOTIDE AND PROTEIN SEQUENCES OF A TRANSMEMBRANE SERINE PROTEASE AND METHODS BASED THEREOF"; and to U.S. provisional application Serial No. [06/234,840]

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

60/234,840 to Edwin L. Madison, Edgar O. Ong and Jiunn-Chern Yeh, filed September 22, 2000, entitled "NUCLEIC ACID MOLECULES ENCODING TRANSMEMBRANE SERINE PROTEASES, THE ENCODED PROTEINS AND METHODS BASED THEREON" is claimed herein. Benefit of priority under 35 U.S.C. §120 to U.S. application Serial No. [09/657,968] 09/657,986, to Edwin L. Madison, Joseph Edward Semple, Gary Samuel Coombs, John Eugene Reiner, Edgar O. Ong, Gian Luca Araldi, filed September 8, 2000, entitled "INHIBITORS OF SERINE PROTEASE ACTIVITY OF MATRIPTASE OR MTSP1" is also claimed herein. This application is a continuation-in-part of U.S. application Serial No. 09/657,986. For international purposes, benefit of priority to each of the above-noted applications is claimed herein.

Please amend the paragraph on page 2, lines 1-6, as follows:

This application is related to U.S. provisional application Serial No. 60/166,391 to Edwin L. Madison and Edgar O. Ong, filed November 18, 1999 entitled "NUCLEOTIDE AND PROTEIN SEQUENCES OF PROTEASE DOMAINS OF ENDOTHELIASE AND METHODS BASED THEREON". This [a] application is also related to International PCT application No. PCT/US00/31803, filed November 17, 2000.

Please amend the paragraph on page 3, lines 24-30, as follows:

A class of extracellular matrix degrading enzymes have been implicated in tumor invasion. Among these are the matrix metalloproteinases (MMP). For example, the production of the matrix metalloproteinase stromelysin is associated with malignant tumors with metastatic potential (see, *e.g.*, [McDonnell] Matrisian *et al.* (1990) *Smnrs. in Cancer Biology* 1:107-115; McDonnell *et al.* (1990) *Cancer and Metastasis Reviews* 9:309-319).

Please amend the paragraph on pages 4, line 20, to page 5, line 17, as follows:

Cell surface proteolysis is a mechanism for the generation of biologically active proteins that mediate a variety of cellular functions. These membrane-anchored proteins, include a disintegrin-like and metalloproteinase (ADAM) and

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

membrane-type matrix metalloproteinase (MT-MMP). In mammals, at least 17 members of the family are known, including seven in humans (see, Hooper *et al.* (2001) *J. Biol. Chem.* 276:857-860). These include: corin (accession nos. AF133845 and AB013874; see, Yan *et al.* (1999) *J. Biol. Chem.* 274:14926-14938; Tomia *et al.* (1998) *J. Biochem.* 124:784-789; [Uan] Yan *et al.* (2000) *Proc. Natl. Acad. Sci. U.S.A.* 97:8525-8529); enterpeptidase (also designated enterokinase; accession no. U09860 for the human protein; see, Kitamoto *et al.* (1995) *Biochem.* 27: 4562-4568; Yahagi *et al.* (1996) *Biochem. Biophys. Res. Commun.* 219:806-812; Kitamoto *et al.* (1994) *Proc. Natl. Acad. Sci. U.S.A.* 91:7588-7592; Matsushima *et al.* (1994) *J. Biol. Chem.* 269:19976-19982;); human airway trypsin-like protease (HAT; accession no. AB002134; see Yamaoka *et al.* *J. Biol. Chem.* 273:11894-11901); MTSP1 and matriptase (also called TADG-15; see SEQ ID Nos. 1 and 2; accession nos. AF133086/AF118224, AF04280022; Takeuchi *et al.* (1999) *Proc. Natl. Acad. Sci. U.S.A.* 96:11054-1161; Lin *et al.* (1999) *J. Biol. Chem.* 274:18231-18236; Takeuchi *et al.* (2000) *J. Biol. Chem.* 275:26333-26342; and Kim *et al.* (1999) *Immunogenetics* 49:420-429); hepsin (see, accession nos. M18930, AF030065, X70900; Leytus *et al.* (1988) *Biochem.* 27: 11895-11901; Vu *et al.* (1997) *J. Biol. Chem.* 272:31315-31320; and Farley *et al.* (1993) *Biochem. Biophys. Acta* 1173:350-352; and see, U.S. Patent No. 5,972,616); TMPRS2 (see, Accession Nos. U75329 and AF113596; Paoloni-Giacobino *et al.* (1997) *Genomics* 44:309-320; and Jacquinet *et al.* (2000) *FEBS Lett.* 468: 93-100); and TMPRSS4 (see, Accession No. NM 016425; Wallrapp *et al.* (2000) *Cancer* 60:2602-2606).

Please amend the paragraph on pages 8, line 15, to page 10, line 13, as follows:

The protease domains generated herein, however, do not result from activation, which produces a two chain activated product, but rather are single chain polypeptides with the N-terminus include the consensus sequence ↓VVG, ↓IVG, ↓VGL, ↓ILG or ↓IVN or other such motif at the N-

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

terminus. As shown herein, such polypeptides, although not the result of activation and not double-chain forms, exhibit proteolytic (catalytic) activity. These protease domain polypeptides are used in assays to screen for agents that modulate the activity of the MTSP. Such assays are also provided herein. In exemplary assays, the effects of test compounds on the ability of a protease domain to proteolytically cleave a known substrate, typically a fluorescently, chromogenically or otherwise detectably labeled substrate, are assessed. Agents, generally compounds, particularly small molecules, that modulate the activity of the protease domain are candidate compounds for modulating the activity of the MTSP. The protease domains can also be used to produce single-chain protease-specific antibodies. The protease domains provided herein include, but are not limited to, the single chain region having an N-terminus at the cleavage site for activation of the zymogen, through the C-terminus, or C-terminal truncated portions thereof that exhibit proteolytic activity as a single-chain polypeptide in *in vitro* proteolysis assays, of any MTSP family member, preferably from a mammal, including and most preferably human, that, for example, is expressed in tumor cells at different levels from non-tumor cells, and that is not expressed on an endothelial cell. These include, but are not limited to: MTSP1 (or matriptase), MTSP3, MTSP4 and MTSP6. Other MTSP protease domains of interest herein, particularly for use in *in vitro* drug screening proteolytic assays, include, but are not limited to: corin (accession nos. AF133845 and AB013874; see, Yan *et al.* (1999) *J. Biol. Chem.* 274:14926-14938; Tomia *et al.* (1998) *J. Biochem.* 124:784-789; [Uan] Yan *et al.* (2000) *Proc. Natl. Acad. Sci. U.S.A.* 97:8525-8529; SEQ ID Nos. 61 and 62 for the human protein); enterpeptidase (also designated enterokinase; accession no. U09860 for the human protein; see, Kitamoto *et al.* (1995) *Biochem.* 27: 4562-4568; Yahagi *et al.* (1996) *Biochem. Biophys. Res. Commun.* 219:806-812; Kitamoto *et al.* (1994) *Proc. Natl. Acad. Sci. U.S.A.* 91:7588-7592; Matsushima *et al.* (1994) *J. Biol. Chem.* 269:19976-19982; see SEQ ID Nos. 63 and 64 for the human protein); human airway trypsin-like protease (HAT; accession no.

U.S.S.N 09/776,191

MADISON *et al.*

PRELIMINARY AMENDMENT ATTACHMENT

AB002134; see Yamaoka *et al.* *J. Biol. Chem.* 273:11894-11901; SEQ ID Nos. 65 and 66 for the human protein); hepsin (see, accession nos. M18930, AF030065, X70900; Leytus *et al.* (1988) *Biochem.* 27: 11895-11901; Vu *et al.* (1997) *J. Biol. Chem.* 272:31315-31320; and Farley *et al.* (1993) *Biochem. Biophys. Acta* 1173:350-352; SEQ ID Nos. 67 and 68 for the human protein); TMPRS2 (see, Accession Nos. U75329 and AF113596; Paoloni-Giacobino *et al.* (1997) *Genomics* 44:309-320; and Jacquinet *et al.* (2000) *FEBS Lett.* 468: 93-100; SEQ ID Nos. 69 and 70 for the human protein) TMPRSS4 (see, Accession No. NM 016425; Wallrapp *et al.* (2000) *Cancer* 60:2602-2606; SEQ ID Nos. 71 and 72 for the human protein); and TADG-12 (also designated MTSP6, see SEQ ID Nos. 11 and 12; see International PCT application No. WO 00/52044, which claims priority to U.S. application Serial No. 09/261,416).

Also provided are muteins of the single chain protease domains and MTSPs, particularly muteins in which the Cys residue in the protease domain that is free (*i.e.*, does not form disulfide linkages with any other Cys residue in the protein) is substituted with another amino acid substitution, preferably with a conservative amino acid substitution or a [substitution] substitution that does not eliminate the activity, and muteins in which a glycosylation site(s) is eliminated. Muteins in which other conservative amino acid substitutions in which catalytic activity is retained are also contemplated (see, *e.g.*, Table 1, for exemplary amino acid substitutions). See, also, Figure 4, which identifies the free Cys residues in MTSP3, MTSP4 and MTSP6.

Please amend the paragraphs on page 11, line 9, to page 12, line 8, as follows:

Additionally provided herein are antibodies that specifically bind to the MTSPs, cells, combinations, kits and articles of manufacture that contain the nucleic acid encoding the MTSP and/or the MTSP. Further provided herein are prognostic, diagnostic, therapeutic screening methods using MTSPs and the nucleic acids encoding MTSP. Also provided are transgenic non-human animals bearing inactivated genes encoding the MTSP and bearing the genes encoding

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

the MTSP under non-native promotor control[are provided]. Such animals are useful in animal models of tumor [initiation] initiation, growth and/or progression models.

Provided herein are members of a family of membrane serine proteases (MTSP) that are expressed in certain tumor or cancer cells such lung, prostate, colon and breast cancers. In particular, it is shown herein, that MTSPs, particularly, MTSP3, MTSP4 and MTSP6 are expressed in lung carcinoma, breast carcinoma, colon adenocarcinoma and/or ovarian carcinomas as well as in certain normal cells and tissues (see *e.g.*, EXAMPLES for tissue-specific expression profiles of each protein exemplified herein). The MTSPs that are of particular interest herein, are those that are expressed in tumor cells, for example, those that appear to be expressed at different levels in tumor cells from normal cells, or whose functional activity is different in tumor cells from normal cells, such as by an alteration in a substrate therefor, or a cofactor. Hence the MTSP provided herein can serve as diagnostic markers for certain tumors. The level of activated MTSP3, MTSP4 and MTSP6 can be diagnostic of prostate cancer. In addition, MTSP4 is expressed and/or activated in lymphomas, leukemias, lung [caner] cancer, breast, prostrate and colon cancers. MTSP6 is activated and/or expressed in breast, lung, prostate, colon and ovarian cancers. Furthermore, compounds that modulate the activity of these MTSPs, as assessed by the assays provided herein, particularly the *in vitro* proteolytic assays that use the single chain protease domains, are potential therapeutic candidates for treatment of various malignancies and neoplastic disease.

Please amend the paragraph on page 16, lines 15-24, as follows:

Also provided are methods of treatments of tumors by administering a prodrug that is activated by an MTSP that is expressed or active in tumor cells, particularly those in which its functional activity in tumor cells is greater than in none-tumor cells. The prodrug is administered and, upon administration, active MTSP expressed on cells cleaves the prodrug and releases active drug in the vicinity of these cells. The active anti-cancer drug accumulates in the vicinity of

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

the tumor. This is particularly useful in instances in [whit] which an MTSP is expressed or active in greater quantity, higher level or predominantly in tumor cells compared to other cells.

Please amend the paragraph on page 19, lines 3-24, as follows:

Exemplary MTSP proteins, with the protease domains indicated, are illustrated in Figures 1-3. Smaller portions thereof that retain protease activity are contemplated. The protease domains vary in size and constitution, including insertions and deletions in surface loops. They retain conserved structure, including at least one of the active site triad, primary specificity pocket, oxyanion hole and/or other features of serine protease domains of proteases. Thus, for purposes herein, the protease domain is a portion of a MTSP, as defined herein, and is homologous to a domain of other MTSPs, such as corin, enterpeptidase, human airway trypsin-like protease (HAT), MTSP1, TMPRSS2, and TMPRSS4, which have been previously identified; it was not recognized, however, that an isolated single chain form of the protease domain could function proteolytically in *in vitro* assays. As with the larger class of [enzymnes] enzymes of the chymotrypsin (S1) fold (see, *e.g.*, Internet accessible MEROPS data base), the MTSPs protease domains share a high degree of amino acid sequence identity. The His, Asp and Ser residues necessary for activity are present in conserved motifs. The activation site, which results in the N-terminus of second chain in the two chain forms is has a conserved motif and readily can be identified (see, *e.g.*, amino acids 801-806, SEQ ID No. 62; amino acids 406-410, SEQ ID No. 64; amino acids 186-190, SEQ ID No. 66; amino acids 161-166, SEQ ID No. 68; amino acids 255-259, SEQ ID No. 70; amino acids 190-194, SEQ ID No. 72).

Please amend the paragraph on pages 20, line, to page 21, line 28, as follows:

Significantly, it is shown herein, that, at least *in vitro*, the single chain forms of the MTSPs and the catalytic domains or proteolytically active portions thereof (typically C-terminal [truncations] truncation) thereof exhibit protease

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

activity. Hence provided herein are isolated single chain forms of the protease domains of MTSPs and their use in *in vitro* drug screening assays for identification of agents that modulate the activity thereof.

As used herein an MTSP3, whenever referenced herein, includes at least one or all of or any combination of:

- a polypeptide encoded by the sequence of nucleotides set forth in SEQ ID No. 3;

- a polypeptide encoded by a sequence of nucleotides that hybridizes under conditions of low, moderate or high stringency to the sequence of nucleotides set forth in SEQ ID No. 3;

- a polypeptide that comprises the sequence of amino acids set forth as amino acids 205-437 of SEQ ID No. 4;

- a [polypeptide] polypeptide that comprises a sequence of amino acids having at least about 85% or 90% sequence identity with the sequence of amino acids set forth in SEQ ID No. 4; and/or

- a splice variant of the MTSP3 set forth in SEQ ID Nos. 3 and 4.

The MTSP3 may be from any animal, particularly a mammal, and includes but are not limited to, humans, rodents, fowl, ruminants and other animals. The full length zymogen or double chain activated form is contemplated or any domain thereof, including the protease domain, which can be a double chain activated form, or a single chain form.

As used herein an MTSP4, whenever referenced herein, includes at least one or all of or any combination of:

- a polypeptide encoded by the sequence of nucleotides set forth in any of SEQ ID No. 5, 7 or 9;

- a polypeptide encoded by a sequence of nucleotides that hybridizes under conditions of low, moderate or high stringency to the sequence of nucleotides set forth in any of SEQ ID Nos. 5, 7 or 9;

- a polypeptide that comprises the sequence of amino acids set forth in any of SEQ ID Nos. 6, 8 or 10;

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

a [polypeptide] polypeptide that comprises a sequence of amino acids having at least about 85% or 90% or 95% sequence identity with the sequence of amino acids set forth in SEQ ID No. 6, 8 or 10; and/or

a splice variant of the MTSP4s set forth in SEQ ID Nos. 7-10.

The MTSP4 may be from any animal, particularly a mammal, and includes but are not limited to, humans, rodents, fowl, ruminants and other animals. The full length zymogen or double chain activated form is contemplated or any domain thereof, including the protease domain, which can be a double chain activated form, or a single chain form.

As used herein an MTSP6, whenever referenced herein, includes at least one or all of or any combination of:

a polypeptide encoded by the sequence of nucleotides set forth in any of SEQ ID No. 11;

a polypeptide encoded by a sequence of nucleotides that hybridizes under conditions of low, moderate or high stringency to the sequence of nucleotides set forth in any of SEQ ID Nos. 11;

a polypeptide that comprises the sequence of amino acids set forth in any of SEQ ID Nos. 12;

a [polypeptide] polypeptide that comprises a sequence of amino acids having at least about 90% or 95% or 98% sequence identity with the sequence of amino acids set forth in SEQ ID No. 12; and/or

a splice variant of the MTSP4s set forth in SEQ ID No. 12.

Please amend the paragraph on page 22, lines 19-26, as follows:

As used herein, a "propeptide" or "pro sequence" is sequence of amino acids positioned at the amino terminus of a mature biologically active polypeptide. When so-positioned, the resulting polypeptide is called a zymogen. Zymogens, generally, are biologically inactive and can be converted to mature active polypeptides by catalytic or autocatalytic cleavage of the propeptide from the zymogen. A [zymogens] zymogen is an enzymatically inactive protein that

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

is converted to a proteolytic enzyme by the action of an activator. Cleavage may be effected autocatalytically.

Please amend the paragraph on page 25, lines 4-15, as follows:

As used herein, the protease domain of an endotheliase refers to the polypeptide portion of the endotheliase that is the extracellular portion that exhibits protease activity. The protease domain is a polypeptide that includes at least the minimum number of amino acids, generally more than 50 or 100, required for protease activity. Protease activity may be assessed empirically, such as by testing the polypeptide for its ability to act as a protease. Assays, such as [in] the assays described in the EXAMPLES, [except] employing a known substrate in place of the test compounds [as described in the Examples] may be used. Furthermore, since proteases, particularly serine proteases, have characteristic structures and sequences or motifs, the protease domain may be readily identified by such structure and sequence or motif.

Please amend the paragraph on page 31, lines 21-31, as follows:

As used herein, nucleic acids include DNA, RNA and [anlages] analogs thereof, including protein nucleic acids (PNA) and mixture thereof. Nucleic acids can be single or double stranded. When referring to probes or primers, optionally labeled, with a detectable label, such as a fluorescent or radiolabel, single-stranded molecules are contemplated. Such molecules are typically of a length such that they are statistically unique of low copy number (typically less than 5, preferably less than 3) for probing or priming a library. Generally a probe or primer contains at least 14, 16 or 30 contiguous of sequence complementary to or identical to a gene of interest. Probes and primers can be 10, 20, 30, 50, 100 or more nucleic acids long.

Please amend the paragraph on page 37, lines 28-30, as follows:

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

As used herein, a combination refers to any association between two or among more items.

As used herein, a composition refers to [a] any mixture. It may be a solution, a suspension, liquid, powder, a paste, aqueous, non-aqueous or any combination thereof.

Please amend the paragraph on page 49, lines 3-15, as follows:

The MTSPs are a family of transmembrane serine proteases that are found in mammals and also other species that share a number of common structural features including: a proteolytic extracellular C-terminal domain; a transmembrane domain, with a hydrophobic domain near the N-terminus; a short cytoplasmic domain; and a variable length stem region containing modular domains. The proteolytic domains share sequence [homologoy] homology including conserved his, asp, and ser residues necessary for catalytic activity that are present in conserved motifs. The MTSPs are synthesized as zymogens, and activated to double chain forms by cleavage. It is shown herein that the single chain proteolytic domain can function *in vitro* and, hence is useful in *in vitro* assays for identifying agents that modulate the activity of members of this family. Also provided are family members designated MTSP3, MTSP4 and an MTSP6 variant.

Please amend the paragraph on page 50, lines 1-15, as follows:

The MTSP may serve as a diagnostic marker for tumors. It is shown herein, that MTSP3 and MTSP4 and the MTSP6 variant provided herein are expressed and/or activated in certain tumors; hence their activation or expression may serve as a diagnostic marker for tumor [developement] development, growth and/or progression. In other instances the MTSP protein can exhibit altered activity by virtue of a change in activity or expression of a co-factor therefor or a substrate therefor. In addition, in some instances, these MTSPS and/or variants thereof may be shed from cell surfaces. Detection of the shed MTSPS, particularly the extracellular domains, in body fluids, such as serum, blood, saliva, cerebral spinal fluid, synovial fluid and interstitial fluids,

urine, sweat and other such fluids and secretions, may serve as a diagnostic tumor marker. In particular, detection of higher levels of such shed polypeptides in a subject compared to a subject known not to have any neoplastic disease or compared to earlier samples from the same subject, can be indicative of neoplastic disease in the subject.

Please amend the paragraph on page 54, lines 21-27, as follows:

Except for the MTSP proteins (MTSP3 and MTSP4) heretofore unidentified and provided herein, the isolated polypeptides contain the MTSP protease domain or a catalytically active portion thereof and, generally, do not contain additional MTSP. Hence isolated, substantially pure proteases, [that e the] protease domains or catalytically active portion thereof in single chain form of MTSPs are provided. The protease domains may be included in a longer protein, but such longer protein is not the MTSP zymogen.

Please amend the paragraph on page 64, lines 8-25, as follows:

C. Tumor specificity and tissue expression profiles

Each MTSP has a characteristic tissue expression profile; the MTSPs in particular, although not exclusively expressed or activated in tumors, exhibit characteristic tumor tissue expression or activation profiles. In some instances, MTSPs may have different activity in a tumor cell from a non-tumor cell by virtue of a change in a substrate or cofactor [therefor] thereof or other factor that would alter the apparent [of] functional activity of the MTSP. Hence each can serve as a diagnostic marker for particular tumors, by virtue of a level of activity and/or expression or function in a subject (i.e. a mammal, particularly a human) with neoplastic disease, compared to a subject or subjects that do not have the neoplastic disease. In addition, detection of activity (and/or expression) in a particular tissue can be indicative of neoplastic disease. Shed MTSPs in body fluids can be indicative of neoplastic disease. Also, by virtue of the activity and/or expression profiles of each, they can serve as therapeutic targets, such as by administration of modulators of the activity thereof, or, as by administration of a prodrug specifically activated by one of the MTSPs.

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

Please amend the paragraph on page 65, lines 5-28, as follows:

The MTSP4 transcript, a DNA fragment encoding part of the LDL receptor domain and the protease domain was used to probe an RNA blot composed of 76 different human tissues (catalog number 7775-1; human multiple tissue expression (MTE) array; CLONTECH). As in the northern analysis of gel blot, a very strong signal was observed in the liver. Signals in other tissues were observed in (decreasing signal level): fetal liver > heart = kidney = adrenal gland = testis = fetal heart and kidney = skeletal muscle = bladder = placenta > brain = spinal cord = colon = stomach = spleen = lymph node = bone marrow = trachea = uterus = pancreas = salivary gland = mammary gland = lung. MTSP4 is also expressed less abundantly in several tumor cell lines including HeLa S3 = leukemia K-562 = Burkitt's lymphomas (Raji and Daudi) = colorectal adenocarcinoma (SW480) > lung carcinoma (A549) = leukemia MOLT-4 = leukemia HL-60. PCR of the MTSP4 transcript from cDNA libraries made from several human primary tumors xenografted in nude mice (human tumor multiple tissue cDNA panel, catalog number K1522-1, CLONTECH) was performed using MTSP4-specific primers. The MTSP4 transcript was detected in breast carcinoma (GI-101), lung carcinoma (LX-1), colon adenocarcinoma (GI-112) and pancreatic adenocarcinoma (GI-103). No apparent signal was detected in another form of lung carcinoma (GI-117), colon adenocarcinoma (CX-1), ovarian carcinoma (GI-102)[.] and prostatic adenocarcinoma (PC3). The MTSP4 transcript was also detected in LNCaP and PC-3 prostate cancer cell lines as well as in HT-1080 human fibrosarcoma cell line.

Please amend the paragraph on pages 72, line 22, to page 74 line 16, as follows:

Any methods known to those of skill in the art for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene containing [of] appropriate transcriptional/translational control signals and protein coding sequences. These methods may include *in vitro*

U.S.S.N 09/776,191

MADISON *et al.*

PRELIMINARY AMENDMENT ATTACHMENT

recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequences encoding MTSP protein, or domains, derivatives, fragments or homologs thereof, may be regulated by a second nucleic acid sequence so that the genes or fragments thereof are expressed in a host transformed with the recombinant DNA molecule(s). For example, expression of the proteins may be controlled by any promoter/enhancer known in the art. In a specific embodiment, the promoter is not native to the genes for MTSP protein. Promoters which may be used include but are not limited to the SV40 early promoter (Bernoist and Chambon, *Nature* 290:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell* 22:787-797 (1980)), the herpes thymidine kinase promoter (Wagner et al., *Proc. Natl. Acad. Sci. USA* 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature* 296:39-42 (1982)); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Kamaroff et al., *Proc. Natl. Acad. Sci. USA* 75:3727-3731 (1978)) or the *tac* promoter (DeBoer et al., *Proc. Natl. Acad. Sci. USA* 80:21-25 (1983)); see also "Useful Proteins from Recombinant Bacteria": in *Scientific American* 242:79-94 (1980)); plant expression vectors containing the nopaline synthetase promoter (Herrar-Estrella et al., *Nature* 303:209-213 (1984)) or the cauliflower mosaic virus 35S RNA promoter (Gardner et al., *Nucleic Acids Res.* 9:2871 (1981)), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., *Nature* 310:115-120 (1984)); promoter elements from yeast and other fungi such as the Gal4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, the alkaline phosphatase promoter, and the following animal transcriptional control regions that exhibit tissue specificity and have been used in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., *Cell* 38:639-646 (1984); Ornitz et al., *Cold Spring Harbor Symp. Quant. Biol.* 50:399-409 (1986); MacDonald, *Hepatology* 7:425-515 (1987)); insulin gene control region which is active in pancreatic beta cells

(Hanahan et al., *Nature* 315:115-122 (1985)), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., *Cell* 38:647-658 (1984); Adams et al., *Nature* 318:533-538 (1985); Alexander et al., *Mol. Cell Biol.* 7:1436-1444 (1987)), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., *Cell* 45:485-495 (1986)), albumin gene control region which is active in liver (Pinckert et al., *Genes and Devel.* 1:268-276 (1987)), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., *Mol. Cell. Biol.* 5:1639-1648 (1985); Hammer et al., *Science* 235:53-58 1987)), alpha-1 antitrypsin gene control region which is active in liver (Kelsey et al., *Genes and Devel.* 1:161-171 (1987)), beta globin gene control region which is active in myeloid cells (Mogram et al., *Nature* 315:338-340 (1985); Kollias et al., *Cell* 46:89-94 (1986)), myelin basic protein gene control region which is active in oligodendrocyte cells of the brain (Readhead et al., *Cell* 48:703-712 (1987)), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, *Nature* 314:283-286 (1985)), and gonadotrophic releasing hormone gene control region which is active in gonadotrophs of the hypothalamus (Mason et al., *Science* 234:1372-1378 (1986)).

Please amend the paragraph on page 77, lines 17-27, as follows:

A variety of modification of the MTSP proteins and domains are contemplated herein. An MTSP-encoding nucleic acid molecule may be modified by any of numerous strategies known in the art (Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The sequences can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the gene encoding a domain, derivative or analog of MTSP, care should be taken to ensure that the modified gene retains the original translational reading frame, uninterrupted by translational stop signals, in the gene region where the desired activity is encoded.

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

Please amend the paragraph on page 79, lines 23-30, as follows:

The single chain protease domains, as shown herein, can be used in a variety of methods to identify compounds that modulate the activity thereof. For MTSPs that [are] exhibit higher activity or expression in tumor cells, compounds that inhibit the proteolytic activity are of particular interest. For any MTSPs that are active at lower levels in tumor cells, compounds or agents that enhance the activity are potentially of interest. In all instances the identified compounds will include agents that are candidate cancer treatments.

Please amend the paragraph on page 83, lines 13-18, as follows:

For purposes herein, all binding assays described above are provided for MTSP3, MTSP4 and MTSP6[(CHECK REF)]. For MTSP1 (including any variant thereof) and other such proteases, binding assays that employ the isolated single chain protease domain or a protein containing such domain (other than the MTSP from which the protease is derived) are provided.

Please amend the paragraph on page 90, lines 5-18, as follows:

While the polyclonal antisera produced in this way may be satisfactory for some applications, for pharmaceutical compositions, use of monoclonal preparations is preferred. Immortalized cell lines which secrete the desired monoclonal antibodies may be prepared using the standard method of Kohler *et al.*, (*Nature* 256: 495-7 (1975)) or modifications which effect immortalization of lymphocytes or spleen cells, as is generally known. The immortalized cell lines secreting the desired antibodies are screened by immunoassay in which the antigen is the peptide hapten, polypeptide or protein. When the appropriate immortalized cell culture secreting the desired antibody is identified, the cells can be cultured either *in vitro* or by production *in vivo* via ascites fluid. Of particular interest, are monoclonal antibodies that recognize the catalytic domain of [the] an MTSP, such as an MTSP3, MTSP4 or an MTSP6.

Please amend the paragraph on page 96, lines 19-28, as follows:

[As] An angiogenesis model used to evaluate the effect of a test compound in preventing angiogenesis is described by Min et al., *Canc. Res.*,

U.S.S.N 09/776,191
MADISON et al.
PRELIMINARY AMENDMENT ATTACHMENT

56:2428-2433 (1996). C57BL6 mice receive subcutaneous injections of a Matrigel mixture containing bFGF, as the angiogenesis-inducing agent, with and without the test compound. After five days, the animals are sacrificed and the Matrigel plugs, in which neovascularization can be visualized, are photographed. An experimental animal receiving Matrigel and an effective dose of test compound will exhibit less vascularization than a control animal or an experimental animal receiving a less- or non-effective dose of compound.

Please amend the paragraph on pages 98, line 17, to page 101, line 30, as follows:

Exemplary, but not limiting serine proteases, include the following known serine protease inhibitors are used in the screening assays: Serine Protease Inhibitor 3 (SPI-3) (Chen, M.C., et al., *Citokine*, 11(11):856-862 (1999)); Aprotinin (Iijima, R., et al., *J. Biochem. (Tokyo)*, 126(5):912-916 (1999)); Kazal-type serine protease inhibitor-like proteins (Niimi, T., et al., *Eur. J. Biochem.*, 266(1):282-292 (1999)); Kunitz-type serine protease inhibitor (Ravichandran, S., et al., *Acta Crystallogr. D. Biol. Crystallogr.*, 55(11):1814-1821 (1999)); Tissue factor pathway inhibitor-2/Matrix-associated serine protease inhibitor (TFPI-2/MSPI), (Liu, Y., et al., *Arch. Biochem. Biophys.*, 370(1):112-8 (1999)); Bukunin, ([Cui] Yi, C.Y., et al., *J. Invest. Dermatol.*, 113(2):182-8 (1999)); Nafmostat mesilate (Ryo, R., et al., *Vox Sang.*, 76(4):241-6 (1999)); TPCK (Huang, Y., et al., *Oncogene*, 18(23):3431-9 (1999)); A synthetic cotton-bound serine protease inhibitor (Edwards, J.V., et al., *Wound Repair Regen.*, 7(2):106-18 (1999)); FUT-175 (Sawada, M., et al., *Stroke*, 30(3):644-50 (1999)); Combination of serine protease inhibitor FUT-0175 and thromboxane synthetase inhibitor OKY-046 (Kaminogo, M., et al., *Neurol. Med. Chir. (Tokyo)*, 38(11):704-8; discussion 708-9 (1998)); The rat serine protease inhibitor 2.1 gene (LeCam, A., et al., *Biochem. Biophys. Res. Commun.*, 253(2):311-4 (1998)); A new intracellular serine protease inhibitor expressed in the rat pituitary gland complexes with granzyme B (Hill, R.M., et al., *FEBS Lett.*, 440(3):361-4 (1998)); 3,4-Dichloroisocoumarin (Hammed, A., et al., *Proc. Soc.*

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

Exp. Biol. Med., 219(2):132-7 (1998)); LEX032 (Bains, A.S., et al., *Eur. J. Pharmacol.*, 356(1):67-72 (1998)); N-tosyl-L-phenylalanine chloromethyl ketone (Dryjanski, M., et al., *Biochemistry*, 37(40):14151-6 (1998)); Mouse gene for the serine protease inhibitor neuroserpin (P112) (Berger, P., et al., *Gene*, 214(1-2):25-33 (1998)); Rat serine protease inhibitor 2.3 gene (Paul, C., et al., *Eur. J. Biochem.*, 254(3):538-46 (1998)); Ecotin (Yang, S.Q., et al., *J. Mol. Biol.*, 279(4):945-57 (1998)); A 14 kDa plant-related serine protease inhibitor (Roch, P., et al., *Dev. Comp. Immunol.*, 22(1):1-12 (1998)); Matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI (Rao, C.N., et al., *Int. J. Cancer*, 76(5):749-56 (1998)); ONO-3403 (Hiwasa, T., et al., *Cancer Lett.*, 126(2):221-5 (1998)); Bdellastasin (Moser, M., et al., *Eur. J. Biochem.*, 253(1):212-20 (1998)); Bikunin (Xu, Y., et al., *J. Mol. Biol.*, 276(5):955-66 (1998)); Nafamostat mesilate (Mellgren, K., et al., *Thromb. Haemost.*, 79(2):342-7 (1998)); The growth hormone dependent serine protease inhibitor, Spi 2.1 (Maake, C., et al., *Endocrinology*, 138(12):5630-6 (1997)); Growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor (Kawaguchi, T., et al., *J. Biol. Chem.*, 272(44):27558-64 (1997)); Heat-stable serine protease inhibitor protein from ovaries of the desert locust, *Schistocerca gregaria* (Hamdaoui, A., et al., *Biochem. Biophys. Res. Commun.*, 238(2):357-60 (1997)); Bikunin, (Delaria, K.A., et al., *J. Biol. Chem.*, 272(18):12209-14 (1997)); Human placental bikunin (Marlor, C.W., et al., *J. Biol. Chem.*, 272(10):12202-8 (1997)); Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor (Shimomura, T., et al., *J. Biol. Chem.*, 272(10):6370-6 (1997)); FUT-187, oral serine protease inhibitor, (Shiozaki, H., et al., *Gan To Kagaku Ryoho*, 23(14): 1971-9 (1996)); Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000 (Rao, C.N., et al., *Arch. Biochem. Biophys.*, 335(1):82-92 (1996)); An irreversible isocoumarin serine protease inhibitor (Palencia, D.D., et al., *Biol. Reprod.*, 55(3):536-42 (1996)); 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF) (Nakabo, Y., et al., *J. Leukoc. Biol.*, 60(3):328-36 (1996)); Neuroserpin

U.S.S.N 09/776,191

MADISON *et al.*

PRELIMINARY AMENDMENT ATTACHMENT

(Osterwalder, T., et al., *EMBO J.*, 15(12):2944-53 (1996)); Human serine protease inhibitor alpha-1-antitrypsin (Forney, J.R., et al., *J. Parasitol.*, 82(3):496-502 (1996)); Rat serine protease inhibitor 2.3 (Simar-Blanchet, A.E., et al., *Eur. J. Biochem.*, 236(2):638-48 (1996)); Gebaxate mesilate (parodi, F., et al., *J. Cardiothorac. Vasc. Anesth.*, 10(2):235-7 (1996)); Recombinant serine protease inhibitor, CPTI II (Stankiewicz, M., et al., *Acta Biochim. Pol.*, 43(3):525-9 (1996)); A cysteine-rich serine protease inhibitor (Guamerin II) (Kim, D.R., et al., *J. Enzym. Inhib.*, 10(2):81-91 (1996)); Diisopropylfluorophosphate (Lundqvist, H., et al., *Inflamm. Res.*, 44(12):510-7 (1995)); Nexin 1 (Yu, D.W., et al., *J. Cell Sci.*, 108(Pt 12):3867-74 (1995)); LEX032 (Scalia, R., et al., *Shock*, 4(4):251-6 (1995)); Protease nexin I (Houenou, L.J., et al., *Proc. Natl. Acad. Sci. U.S.A.*, 92(3):895-9 (1995)); Chymase-directed serine protease inhibitor (Woodard S.L., et al., *J. Immunol.*, 153(11):5016-25 (1994)); N-alpha-tosyl-L-lysyl-chloromethyl ketone (TLCK) (Bourinbaiar, A.S., et al., *Cell Immunol.*, 155(1):230-6 (1994)); Smpi56 (Ghendler, Y., et al., *Exp. Parasitol.*, 78(2):121-31 (1994)); Schistosoma haematobium serine protease (Blanton, R.E., et al., *Mol. Biochem. Parasitol.*, 63(1):1-11 (1994)); Spi-1 (Warren, W.C., et al., *Mol. Cell Endocrinol.*, 98(1):27-32 (1993)); TAME (Jessop, J.J., et al., *Inflammation*, 17(5):613-31 (1993)); Antithrombin III (Kalaria, R.N., et al., *Am. J. Pathol.*, 143(3):886-93 (1993)); FOY-305 (Ohkoshi, M., et al., *Anticancer Res.*, 13(4):963-6 (1993)); Camostat mesilate (Senda, S., et al., *Intern. Med.*, 32(4):350-4 (1993)); Pigment epithelium-derived factor (Steele, F.R., et al., *Proc. Natl. Acad. Sci. U.S.A.*, 90(4):1526-30 (1993)); Antistasin (Holstein, T.W., et al., *FEBS Lett.*, 309(3):288-92 (1992)); The vaccinia virus K2L gene encodes a serine protease inhibitor (Zhou, J., et al., *Virology*, 189(2):678-86 (1992)); Bowman-Birk serine protease inhibitor (Werner, M.H., et al., *J. Mol. Biol.*, 225(3):873-89 (1992)); FUT-175 (Yanamoto, H., et al., *Neurosurgery*, 30(3):358-63 (1992)); FUT-175; (Yanamoto, H., et al., *Neurosurgery*, 30(3):351-6, discussion 356-7 (1992)); PAI-I (Yreadwell, B.V., et al., *J. Orthop. Res.*, 9(3):309-16 (1991)); 3,4-

U.S.S.N 09/776,191

MADISON *et al.*

PRELIMINARY AMENDMENT ATTACHMENT

Dichloroisocoumarin (Rusbridge, N.M., et al., *FEBS Lett.*, 268(1):133-6 (1990)); Alpha 1-antichymotrypsin (Lindmark, B.E., et al., *Am. Rev. Respir. Dis.*, 141(4 Pt 1):884-8 (1990)); P-toluenesulfonyl-L-arginine methyl ester (TAME) (Scuderi, P., *J. Immunol.*, 143(1):168-73 (1989)); Aprotinin (Seto, S., et al., *Adv. Exp. Med. Biol.*, 247B:49-54 (1989)); Alpha 1-antichymotrypsin (Abraham, C.R., et al., *Cell*, 52(4):487-501 (1988)); Contrapsin (Modha, J., et al., *Parasitology*, 96 (Pt 1):99-109 (1988)); (FOY-305) (Yamauchi, Y., et al., *Hiroshima J. Med. Sci.*, 36(1):81-7 No abstract available (1987)); Alpha 2-antiplasmin (Holmes, W.E., et al., *J. Biol. Chem.*, 262(4):1659-64 (1987)); 3,4-dichloroisocoumarin (Harper, J.W., et al., *Biochemistry*, 24(8):1831-41 (1985)); Diisopropylfluorophosphate (Tsutsui, K., et al., *Biochem. Biophys. Res. Commun.*, 123(1):271-7 (1984)); Gabexate mesilate (Hesse, B., et al., *Pharmacol. Res. Commun.*, 16(7):637-45 (1984)); Phenyl methyl sulfonyl fluoride (Dufer, J., et al., *Scand. J. Haematol.*, 32(1):25-32 (1984)); Aprotinin (Seto, S., et al., *Hypertension*, 5(6):893-9 (1983)); Protease inhibitor CI-2 (McPhalen, C.A., et al., *J. Mol. Biol.*, 168(2):445-7 (1983)); Phenylmethylsulfonyl fluoride (Sekar V., et al., *Biochem. Biophys. Res. Commun.*, 89(2):474-8 (1979)); PGE1 (Feinstein, M.D., et al., *Prostaglandine*, 14(6):1075-93 (1977).

Please amend the paragraph on page 108, lines 12-20, as follows:

Antibodies, including polyclonal and monoclonal antibodies, that specifically bind to the MTSP proteins provided herein, particularly to the single chain protease domains thereof are provided. Preferably, the antibody is a monoclonal antibody, and preferably, the antibody specifically binds to the protease domain of the MTSP protein. In particular embodiments, antibodies to each of the single chain of protease domain of MTSP1, MTSP3, MTSP4 and MTSP6. Also provided are antibodies that specifically bind to any domain of MTSP3 or MTSP4, and to double chain forms thereof.

Please amend the paragraph on page 110, lines 19-28, as follows:

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, *e.g.*, ELISA (enzyme-linked

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

immunosorbent assay). To select antibodies specific to a particular domain of the MTSP protein one may assay generated hybridomas for a product that binds to the fragment of the MTSP protein that contains such a domain.

The foregoing antibodies can be used in methods known in the art relating to the localization and/or quantitation of MTSP [protein] proteins, *e.g.*, for imaging these proteins, measuring levels thereof in appropriate physiological samples, in diagnostic methods, etc.

Please amend the paragraph on page 114, lines 10-21, as follows:

Peptides and peptide mimetics that can bind to MTSP proteins or the protease domain of MTSP proteins and modulate the activity thereof, or have MTSP protein activity, can be used for treatment of neoplastic diseases. The peptides and peptide mimetics may be delivered, *in vivo* or *ex vivo*, to the cells of a subject in need of treatment. Further, peptides which have MTSP protein activity can be delivered, *in vivo* or *ex vivo*, to cells which carry mutant or missing alleles encoding the MTSP protein gene. Any of the techniques described herein or known to the skilled artisan can be used for preparation and *in vivo* or *ex vivo* delivery of such peptides and peptide mimetics that are substantially free of other human proteins. For example, the peptides can be readily prepared by expression in a microorganism or synthesis *in vitro*.

Please amend the paragraph on page 120, lines 1-13, as follows:

Covalent attachment of a detectable label to the peptide or peptide mimetic is accomplished by conventional methods well known in the art. For example, when the ^{125}I radioisotope is employed as the detectable label, covalent attachment of ^{125}I to the peptide or the peptide mimetic can be achieved by incorporating the amino acid tyrosine into the peptide or peptide mimetic and then [iodinating] iodinating the peptide (see, *e.g.*, Weaner *et al.* (1994) *Synthesis and Applications of Isotopically Labelled Compounds*, pp. 137-140). If tyrosine is not present in the peptide or peptide mimetic, incorporation of tyrosine to the N or C terminus of the peptide or peptide mimetic can be achieved by well known chemistry. Likewise, ^{32}P can be

incorporated onto the peptide or peptide mimetic as a phosphate moiety through, for example, a hydroxyl group on the peptide or peptide mimetic using conventional chemistry.

Please amend the paragraph on pages 126, line 20, to page 127, line 25, as follows:

Linkers can be any moiety suitable to associate a domain of MTSP protein and a targeting agent. Such linkers and linkages include, but are not limited to, peptidic linkages, amino acid and peptide linkages, typically containing between one and about 60 amino acids, more generally between about 10 and 30 amino acids, chemical linkers, such as heterobifunctional cleavable cross-linkers, including but are not limited to, N-succinimidyl (4-iodoacetyl)-aminobenzoate, [sulfosuccinimidyl] sulfosuccinimidyl (4-iodoacetyl)-aminobenzoate, 4-succinimidyl-oxycarbonyl-a- (2-pyridyldithio)toluene, sulfosuccinimidyl-6- [a-methyl-a-(pyridyldithiol)-toluamido] hexanoate, N-succinimidyl-3-(-2-pyridyldithio) - [propionate]propionate, succinimidyl 6[3-(-2-pyridyldithio)-[propionamido] propioamido] hexanoate, sulfosuccinimidyl 6[3-(-2-pyridyldithio)-propionamido] hexanoate, 3-(2-pyridyldithio)-propionyl hydrazide, Ellman's reagent, dichlorotriazinic acid, and S-(2-thiopyridyl)-L-cysteine. Other linkers include, but are not limited to peptides and other moieties that reduce steric hindrance between the domain of MTSP protein and the targeting agent, intracellular enzyme substrates, linkers that increase the flexibility of the conjugate, linkers that increase the solubility of the conjugate, linkers that increase the serum stability of the conjugate, photocleavable linkers and acid cleavable linkers.

Other exemplary linkers and linkages that are suitable for chemically linked conjugates include, but are not limited to, disulfide bonds, thioether bonds, hindered disulfide bonds, and covalent bonds between free reactive groups, such as amine and thiol groups. These bonds are produced using heterobifunctional reagents to produce reactive thiol groups on one or both of the polypeptides and then reacting the thiol groups on one polypeptide with reactive thiol groups or amine groups to which reactive maleimido groups or

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

thiol groups can be attached on the other. Other linkers include, acid cleavable linkers, such as bismaleimideethoxy propane, acid labile-transferrin conjugates and adipic acid [dihydrazide] dihydrazide, that would be cleaved in more acidic intracellular compartments; cross linkers that are cleaved upon exposure to UV or visible light and linkers, such as the various domains, such as C_H1, C_H2, and C_H3, from the constant region of human IgG₁ (see, Batra *et al. Molecular Immunol.*, 30:379-386 (1993)). In some embodiments, several linkers may be included in order to take advantage of desired properties of each linker.

Please amend the paragraph on pages 149, line 18, to page 150, line 3, as follows:

The MTSP protein antisense nucleic acids are of at least six nucleotides and are preferably oligonucleotides (ranging from 6 to about 150 nucleotides, or more preferably 6 to 50 nucleotides). In specific aspects, the oligonucleotide is at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 125 nucleotides. The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci. U.S.A.* 84:648-652 (1987); PCT Publication No. WO 88/09810, published December 15, 1988) or blood-brain barrier (see, *e.g.*, PCT Publication No. WO 89/10134, published April 25, 1988), hybridization-triggered cleavage agents (see, *e.g.*, [Krol] Van Der Krol et al., *BioTechniques* 6:958-976 (1988)) or intercalating agents (see, *e.g.*, Zon, *Pharm. Res.* 5:539-549 (1988)).

Please amend the paragraph on page 165, lines 5-13, as follows:

Overexpression of the gene product was achieved in *E. coli* strain BL21(DE3) (Novagen, Madison WI) containing the DNAY plasmid for rare codon optimization (see, *e.g.*, Garcia *et al.* (1986) *Cell* 45:453-459). Cells were grown

U.S.S.N 09/776,191
MADISON *et al.*
PRELIMINARY AMENDMENT ATTACHMENT

at 37 °C in (2xYT) media supplemented with [carbanicillin] carbenicillin and kanamycin to a final concentrations of 50 ug/ml and 34 ug/ml, respectively. One liter cultures were inoculated with 10 mL of an overnight culture grown in the same media. Cells were allowed to grow to a density of 0.6 – 1.0 OD₆₀₀ before the addition of IPTG (final concentration 1.0 mM). Cells were grown an additional 4 hours before harvesting.

IN THE CLAIMS:

Please amend claims 2, 27, 28, and 133 as follows:

2. (Amended) The substantially purified polypeptide of claim 1, wherein the MTSP is not expressed on endothelial cells.

27. (Amended) The [cells] cell of claim 25 that is a eukaryotic cell.

28. (Amended) The cell of claim 25 that is selected from among a bacterial cell, a yeast cell, [a yeast cell,]a plant cell, an insect cell and an animal cell.

133. (Amended) A method of detecting neoplastic disease, comprising: detecting an MTSP3, MTSP4 or MTSP6 of claim 90 in a biological sample, wherein the amount detected differs from the amount [is] in a subject who does not have neoplastic disease.

* * *

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By:


Stephanie Seidman
Registration No. 33, 779

Attorney Docket No. 24745-1607
Address all correspondence to:
Stephanie Seidman
HELLER EHRMAN WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, Suite 600
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com